Therapy for MS Archive - Page 4 of 6

Pharmacovigilance Data on Ocrelizumab

20. July 2020 Prof. Dr. med. Mathias Mäurer Therapy for MS

In view of a number of inquiries, I assume that a work recently published in the journal Multiple Sclerosis and Related Disorders (MSARD) has caused some confusion. The work deals with the occurrence of COVID-19

Future of MS Therapy? – News on BTK Inhibitors

4. May 2020 Prof. Dr. med. Mathias Mäurer Therapy for MS

B lymphocytes are currently of great importance for therapy research in MS. They are a central element in the pathogenesis of MS, on the one hand as important antigen-presenting cells, on the other hand as

Lemtrada – what’s next?

6. March 2020 Prof. Dr. med. Mathias Mäurer Therapy for MS

During the past year, the MS drug Lemtrada was reviewed by the European Medicines Agency (EMA) for its benefit-risk ratio. The basis for this so-called §20 procedure were reports of serious side effects, in some

The New S1P Modulators

2. December 2019 Prof. Dr. med. Mathias Mäurer Therapy for MS

In addition to the study data from Ofatumumab, which I had already reported on (see DocBlog post from September 2019), another new study program was presented at ECTRIMS 2019 in Stockholm. It is the so-called

Evaluation of the Benefit-Risk Ratio of Alemtuzumab (Lemtrada)

12. July 2019 Prof. Dr. med. Mathias Mäurer Therapy for MS

Many of you may have noticed, but especially patients who have been treated with Lemtrada, are concerned that the European Medicines Agency (EMA) initiated a safety procedure on April 11, 2019 to assess the benefit-risk

MS Medication and Pregnancy

9. January 2019 Prof. Dr. med. Mathias Mäurer Therapy for MS

The desire to have children and MS is an important topic. Today, all experts agree that people with MS should be intensively supported on this subject. Everything should be done to realize the desire to

Switching from Natalizumab to Ocrelizumab

5. October 2018 Prof. Dr. med. Mathias Mäurer Therapy for MS

Tysabri® (active ingredient Natalizumab) is a highly effective medication, but it has the significant problem of PML risk – you have already read this statement here quite often. Despite this serious side effect, I advocate

“Extended Dosing” with Natalizumab – A Sensible Strategy for Reducing the Risk of PML?

9. August 2018 Prof. Dr. med. Mathias Mäurer Therapy for MS

Tysabri® (Natalizumab) is undoubtedly a very effective and well-tolerated drug for the treatment of active Multiple Sclerosis. Many patients have benefited from the treatment in the past and were satisfied with the effects and individual

“Blood Cleansing” for MS?!

18. July 2018 Prof. Dr. med. Mathias Mäurer Therapy for MS

When “blood washing” is discussed in relation to MS, this refers to certain plasma exchange procedures that can be used in severe MS relapses if cortisone has not produced sufficient effects.

Approval of Daclizumab withdrawn

11. April 2018 Prof. Dr. med. Mathias Mäurer Therapy for MS

Recently, the company Biogen, in consultation with the European Medicines Agency (EMA), withdrew the approval of the MS drug Daclizumab. The reason was that, in addition to a death due to an autoimmune liver inflammation,

Category: Therapy for MS

Pharmacovigilance Data on Ocrelizumab

Future of MS Therapy? – News on BTK Inhibitors

Lemtrada – what’s next?

The New S1P Modulators

Evaluation of the Benefit-Risk Ratio of Alemtuzumab (Lemtrada)

MS Medication and Pregnancy

Switching from Natalizumab to Ocrelizumab

“Extended Dosing” with Natalizumab – A Sensible Strategy for Reducing the Risk of PML?

“Blood Cleansing” for MS?!

Approval of Daclizumab withdrawn

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community